doi: 10.1016/j.aohep.2020.10.008.
- PMID: 33157269
- DOI: 10.1016/j.aohep.2020.10.008
Abstract
Introduction and objectives: Previous studies reveal conflicting data on the effect of cannabis use in patients with cirrhosis. This research evaluates the impact of cannabis on hepatic decompensation, health care utilization, and mortality in patients with cirrhosis.
Material and methods: A retrospective analysis of the State Inpatient Database (SID) was performed evaluating patients from Colorado and Washington in 2011 to represent pre-cannabis legalization and 2015 to represent post-cannabis legalization. Multivariable analysis was performed to study the impact of cannabis on the rate of admissions with hepatic decompensations, healthcare utilization, and mortality in patients with cirrhosis.
Results: Cannabis use was detected in 370 (2.1%) of 17,520 cirrhotics admitted in 2011 and in 1,162 (5.3%) of 21,917 cirrhotics in 2015 (p-value <0.001). On multivariable analysis, cirrhotics utilizing cannabis after its legalization experienced a decreased rate of admissions related to hepatorenal syndrome (Odds Ratio (OR): 0.51; 95% Confidence Interval (CI): 0.34-0.78) and ascites (OR: 0.73; 95% CI: 0.63-0.84). Cirrhotics with an etiology of disease other than alcohol and hepatitis C had a higher risk of admission for hepatic encephalopathy if they utilized cannabis [OR: 1.57; 95% CI: 1.16-2.13]. Decreased length of stay (-1.15 days; 95% CI: -1.62, -0.68), total charges (-$15,852; 95% CI: -$21,009, -$10,694), and inpatient mortality (OR: 0.68; 95% CI: 0.51-0.91) were also observed in cirrhotics utilizing cannabis after legalization compared to cirrhotics not utilizing cannabis or utilizing cannabis prior to legalization.
Conclusion: Cannabis use in patients with cirrhosis resulted in mixed outcomes regarding hospital admissions with hepatic decompensation. A trend towards decreased hospital utilization and mortality was noted in cannabis users after legalization. These observations need to be confirmed with a longitudinal randomized study.
Keywords: Cannabis, Cirrhosis, Decompensation, Hospital Utilization, Patient Outcomes
Copyright © 2020. Published by Elsevier España, S.L.U.
Similar articles
-
Changes in Healthcare Encounter Rates Possibly Related to Cannabis or Alcohol following Legalization of Recreational Marijuana in a Safety-Net Hospital: An Interrupted Time Series Analysis.J Addict Med. 2019 May/Jun;13(3):201-208. doi: 10.1097/ADM.0000000000000480.PMID: 30475257
-
Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective.Am J Gastroenterol. 2010 Jan;105(1):106-13. doi: 10.1038/ajg.2009.615. Epub 2009 Oct 20.PMID: 19844204
-
Deleterious effect of cirrhosis on outcomes after motor vehicle crashes using the nationwide inpatient sample.Am J Gastroenterol. 2008 Jul;103(7):1674-81. doi: 10.1111/j.1572-0241.2008.01814.x. Epub 2008 Jul 4.PMID: 18616657
-
Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA.BMJ Open. 2019 May 15;9(5):e027432. doi: 10.1136/bmjopen-2018-027432.PMID: 31092662 Free PMC article.
-
[The Road towards the Responsible and Safe Legalization of Cannabis Use in Portugal].Acta Med Port. 2018 Feb 28;31(2):115-125. doi: 10.20344/amp.10093. Epub 2018 Feb 28.PMID: 29596771 Review. Portuguese.
